System and method for assessing a risk of bone loss in a patient
OwnerJoseph W. GALVIN, Zachary T. COLBURNinventors
Life of this patent
Estimating the term…
Abstract
A method is provided for assessing a risk of bone loss in a patient. The method includes receiving, at a processor, first data that indicates measured values of a panel of biomarkers in a sample from a patient. A value of each biomarker in the panel corresponds to a level of the biomarker in the sample. The method also includes determining, with the processor, second data that indicates a prediction that the patient has bone loss above a threshold value based on the first data and a classifier model. A method is also provided for determining the classifier model. A system is further provided for performing one of the disclosed methods.
Claims28
A method comprising:
- a) receiving, at a processor, first data that indicates measured values of a panel of biomarkers in a sample from a patient;
- and
- b) determining, with the processor, second data that indicates a prediction that the patient has bone loss above a threshold value based on the first data and a classifier model trained on values of the panel of biomarkers as input and observed bone loss above a threshold value as output, and wherein the method optionally further comprises (i) transmitting, with the processor, a signal to a display to output third data on the display based on the determined prediction;
- and/or (ii) measuring, with a device, the values of the panel of biomarkers in the sample.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A test kit to determine the levels of glenoid bone loss biomarker gene expression using a real time quantitative polymerase chain reaction (rt-qPCR) or multiplex-qPCR, comprising;
- oligonucleotide primers complementary to the target sequences of IFIT1 and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding IFIT1;
- oligonucleotide primers complementary to the target sequences of IFIT3 and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding IFIT3;
- oligonucleotide primers complementary to the target sequences of IFI44 and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding IFI44;
- oligonucleotide primers complementary to the target sequences of PRKCB and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding PRKCB;
- oligonucleotide primers complementary to the target sequences of OAS2 and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding OAS2;
- and
- oligonucleotide primers complementary to the target sequences of a housekeeping gene and probes comprising oligonucleotide complementary to another target sequence in the 3′ direction of the primers and labeled with detachable fluorophore for mRNA encoding housekeeping gene, wherein at least one housekeeping gene is selected from CLTC, GAPDH, GUSB, HPRT1, PGK1, or TUBB;
- wherein the fluorophores of individual probes can be the same or different in real time qPCR, and wherein the fluorophores of individual probes are different from each other in multiplex qPCR.
A method of diagnosing and treating a subject suffering from glenoid bone loss, comprising:
- determining whether the subject has glenoid bone loss by measuring an amount of expression products of marker genes in a sample from the subject, wherein the marker genes are selected from IFIT1, IFIT3, IFI44, PRKCB, and/or OAS2;
- wherein when levels of the expression products comprises a deviation relative to control level, indicates glenoid bone loss in the subject;
- and
- Performing surgery on the subject selected from open Latarjet procedure, augmentation with an iliac crest bone graft, glenoid osteochondral allograft, or distal tibia osteochondral allograft.
Dependencies are inferred from the claim text.